Psychedelic Liberty Summit
Saturday, April 25th
Moderator: Julie Holland
Featured speaker: Monnica T. Williams
Recently, there has been much excitement in the potential of psychedelic-assisted psychotherapy to address a multitude of mental health conditions, including depression, posttraumatic stress disorder, addiction, end-of-life anxiety, and others. The non-profit organization Multidisciplinary Association of Psychedelic Studies (MAPS) has been funding studies to demonstrate the efficacy of psychedelics for mental health, including MDMA-assisted psychotherapy for people with PTSD. Thanks to these efforts, FDA approval of MDMA for the treatment PTSD may soon become a reality. However, not everyone has been included. People of color have not been well-represented as researchers or participants in psychedelic clinical studies worldwide. They have been underrepresented in psychedelic therapist training programs. As psychedelics move toward becoming commercially available, factors uniquely impacting access for people of color include prohibitive costs, negative stereotypes about people of color and drug use, and stigmas due to criminalization of people of color through the War on Drugs. Addressed are initiatives being taken to reduce these disparities and next steps for creating a culture of inclusivity in the psychedelic community.